All News GSK plc Deutsche Boerse AG

Equities

GS71

GB00BN7SWP63

Real-time Estimate Tradegate Other stock markets 09:17:40 30/04/2024 BST			5-day change	1st Jan Change
19.65 ^EUR	+2.07%		+5.07%	+19.76%

04-29	GSK : UBS reaffirms its Buy rating	ZD
04-29	Hipgnosis Songs Fund backs new Blackstone bid	AN

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GSK : UBS reaffirms its Buy rating	04-29	ZD
Hipgnosis Songs Fund backs new Blackstone bid	04-29	AN
Sector Update: Health Care Stocks Drop in Afternoon Trading	04-25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	04-25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	04-25	MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement	04-25	MT
Moody’s Affirms Haleon’s Ratings on Strong Operating Performance	04-25	MT
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	04-24	MT
Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...	04-24
GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review	04-24	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	04-24	MT
GSK : Gets a Sell rating from JP Morgan	04-24	ZD
GSK : Gets a Buy rating from Bernstein	04-24	ZD
US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer \| GSK	04-24	AQ
GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli	04-24	CI
GSK: FDA priority review for endometrial cancer	04-24	CF
GSK's Jemperli with chemotherapy accepted for priority review by FDA	04-24	AN
GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	04-24	MT
GSK Says U.S. FDA Accepts New Indication Filing For Jemperli	04-24	RE
Edwards Lifesciences Corporation: The story continues	04-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 02:40 pm